Ono Pharmaceutical Co., Ltd.

Masaki Asada

Kousuke Tani

Satonori Higuchi

Kaoru Kobayashi

Masami Narita

Tohru Kotani

Hirotsugu Takano

Masaya Hirobe

Kazuhiro Fuchibe

Ryo Oikawa

Mikio Ogawa

Hidenori Takahashi

Akito Kakuuchi

Yan Zhang

Goran Krilov

Mats Svensson

Anatoly Ruvinsky

Shuhei Umemura

Daigo Inoyama

Atsushi Naganawa

Toshihiko Nagase

Yasuhiro Takeda

Atsushi Kinoshita

Keisuke Hanada

Kazutoyo Sato

Ken Yoshikawa

Kyle Konze

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation is disclosed. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation.

Tricyclic spiro compound

Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EPreceptor antagonistic activity, in preventing and/or treating disease caused by activation of an EPreceptor.

EP4 antagonist

An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): 

DP antagonist

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation is disclosed. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation. 

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation. 

A carboxylic acid derivative of formula (I): wherein Ris &#x2014;COOH, &#x2014;COOR, etc.; A is a single bond, alkylene, etc.; Ris alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and Ris alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGEreceptor, especially subtypes EPand/or EPand show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient

The present invention relates to a carboxylic acid compound of formula (I): wherein Ris H, alkyl; m is 2, 3; n is 0-2; Ris phenyl, naphthyl, benzofuran, benzothiophene; Q is &#x2014;CH&#x2014;O-Cyc1, &#x2014;CH-Cyc2, -L-Cyc3; Rand Reach independently is hydrogen, alkyl or taken together form tetrahydro-2H-pyran; a pharmaceutically acceptable salt thereof, a method for producing a process of the preparation thereof and a pharmaceutical agent comprising the same as an active ingredient. The compound of formula (I) have an antagonizing activity against PGEreceptor, specifically EPreceptor which is subtype thereof, and are useful for the prevention and/or treatment of itching, pain, urinary disturbance or stress disease.

Carboxylic acid compounds

Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient

Growing community of inventors

Osaka, Japan

Masaki Asada